Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 722-727

  Pericleous, Charis ^a   Ruiz Limón, Patricia ^b   Romay Penabad, Zurina ^b   Carrera Marín, Ana ^b   Garza Garcia, Acely ^c   Murfitt, Lucy ^c   Driscoll, Paul C ^c   Latchman, David S ^a   Isenberg, David A ^a   Giles, Ian ^a   Ioannou, Yiannis ^a,d   Rahman, Anisur ^a   Pierangeli, Silvia S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Anti phospholipid antibodies; Anti phospholipid syndrome; Domain i; Mouse model; Venous thrombosis; 2 glycoprotein i

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; DI ANTIBODY; IMMUNOGLOBULIN G; PROCOAGULANT; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IN VIVO STUDY; MALE; MICROCIRCULATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENICITY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DOMAIN; THROMBOSIS;

EID: 84926465767     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu360     Document Type: Article

References (20)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Roubey RA. Antiphospholipid antibodies: immunological aspects. Clin Immunol 2004;112:127-8.
3. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368: 1033-44.
4. Ioannou Y, Pericleous C, Giles I et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007;56: 280-90.
5. Iverson GM, Victoria EJ, Marquis DM. Anti-b2 glycoprotein I (b2GPI) autoantibodies recognize an epitope on the first domain of b2GPI. Proc Natl Acad Sci USA 1998;95: 15542-6.
6. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000;15: 91-6.
7. Iverson GM, Reddel S, Victoria EJ et al. Use of single point mutations in domain I of b2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002;169:7097-103.
8. de Laat B, Pengo V, Pabinger I et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767-73.
9. Ioannou Y, Romay-Penabad Z, Pericleous C et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of b2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42.
10. Pericleous C, Miles J, Esposito D et al. Evaluating the conformation of recombinant domain I of beta(2)-glycoprotein I and its interaction with human monoclonal antibodies. Mol Immunol 2011;49:56-63.
11. Pierangeli SS, Liu X, Espinola R et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000;84:388-95.
12. Giles I, Pericleous C, Liu X et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol 2009;182:4836-43.
13. Carrera-Marin A, Romay-Penabad Z, Papalardo E et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 2012;21: 1497-505.
14. Ioannou Y, Giles I, Lambrianides A et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol 2006;6:8.
15. Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74:1361-7.
16. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011;117: 1408-14.
17. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost 2012;38:360-74.
18. Agostinis C, Durigutto P, Sblattero D et al. A noncomplement-fixing antibody to b2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood 2014;123: 3478-87.
19. Colasanti T, Alessandri C, Capozzi A et al. Autoantibodies specific to a peptide of b2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood 2012;120:3360-70.
20. Pericleous C, Ioannou Y. New therapeutic targets for the antiphospholipid syndrome. Expert opinion on therapeutic targets 2010;14:1291-9.